Firm represents Warburg Pincus and JHP Pharmaceuticals in sale of JHP to Par Pharmaceutical.
On January 21, it was announced that Par Pharmaceutical Companies, Inc. has entered into a definitive agreement to acquire Willkie client JHP Group Holdings, the parent company of JHP Pharmaceuticals, a leading specialty pharmaceutical company that develops, manufactures and markets branded and generic sterile injectable products, for approximately $490 million. JHP is a portfolio company of private equity firm Warburg Pincus. Willkie advised Warburg Pincus and JHP in the transaction.
Based in New Jersey, JHP has a portfolio consisting of a variety of branded products in therapeutic areas including anesthesiology, gastroenterology, infectious disease and women's health. Par Pharmaceutical, a portfolio company of private equity firm TPG, is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals.
Willkie also advised Warburg Pincus in its 2012 acquisition of JHP from Morgan Stanley Principal Investments. The current transaction was handled by a multidisciplinary Willkie deal team led by partners Steven Gartner, Robert Langdon and Thomas Mark, and included partners Jeffrey Goldfarb, Hillel Jacobson and Jordan Messinger; special counsel Miriam Bishop and Jonathan Konoff and associates Joashua Deason, Timothy DeKeyser, Amir Ghavi, Evan Goodman, Jacob Kleinman, Mark Myott, Tej Prakash, Ryan Stott and DJ Stauber.